# The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS

> **NCT03151005** · PHASE4 · COMPLETED · sponsor: **Xinqiao Hospital of Chongqing** · enrollment: 70 (actual)

## Conditions studied

- Polycystic Ovary Syndrome (PCOS)
- Overweight
- Obesity

## Interventions

- **DRUG:** Metformin-GLP-1 Receptor Agonist
- **DRUG:** Metformin-Oral Contraceptive(OC)

## Key facts

- **NCT ID:** NCT03151005
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-01
- **Primary completion:** 2021-04-01
- **Final completion:** 2021-04-23
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2023-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03151005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03151005, "The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03151005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*